{
    "Trade/Device Name(s)": [
        "Atellica IM B.R.A.H.M.S Procalcitonin (PCT)",
        "Atellica IM B.R.A.H.M.S Procalcitonin Calibrator",
        "Atellica IM B.R.A.H.M.S Procalcitonin Quality Control (QC)",
        "Atellica IM B.R.A.H.M.S Procalcitonin Master Curve Material (MCM)"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics Inc.",
    "510(k) Number": "K181002",
    "Predicate Device Reference 510(k) Number(s)": [
        "DEN150009",
        "K171338"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PRI",
        "PMT",
        "PTF",
        "JIT"
    ],
    "Summary Letter Date": "April 13, 2018",
    "Summary Letter Received Date": "April 16, 2018",
    "Submission Date": "June 04, 2018",
    "Regulation Number(s)": [
        "21 CFR 866.3215",
        "21 CFR 862.1150"
    ],
    "Regulation Name(s)": [
        "Device to detect and measure non-microbial analytes in human clinical specimens to aid in assessment of patients with suspected sepsis",
        "Single (specified) analyte calibrators (assayed and unassayed)"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "microbiology"
    ],
    "Analyte(s)": [
        "Procalcitonin"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (EDTA)",
        "Plasma (lithium heparin)",
        "Plasma (sodium heparin)"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Atellica IM Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Sandwich immunoassay",
        "Direct chemiluminescent technology"
    ],
    "Methodologies": [
        "Quantitative measurement",
        "Two-site immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Quality control material",
        "Master curve material"
    ],
    "Document Summary": "FDA 510(k) summary for Atellica IM B.R.A.H.M.S Procalcitonin (PCT) quantitative sandwich immunoassay for procalcitonin measurement on the Atellica IM Analyzer for sepsis assessment.",
    "Indications for Use Summary": "For quantitative determination of procalcitonin in human serum and plasma as an aid in risk assessment for progression to severe sepsis/septic shock, cumulative 28-day mortality in severe sepsis/septic shock, antibiotic therapy decision in lower respiratory tract infections, and antibiotic discontinuation for sepsis, used with other clinical/laboratory findings.",
    "fda_folder": "Microbiology"
}